Compositions for controlling Varroa mites in bees

US10801028B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10801028-B2
Application numberUS-201715498008-A
CountryUS
Kind codeB2
Filing dateApr 26, 2017
Priority dateOct 14, 2009
Publication dateOct 13, 2020
Grant dateOct 13, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising at least one nucleic acid agent which comprises a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite, and wherein said nucleic acid agent does not comprise a permeation enhancing agent selected from the group consisting of a virus, a polyamine, a polycation, a lipopolyamine, an anionic lipid, a neutral lipid, a pH sensitive lipid, transferrin, biotin, a serum protein, a glycoprotein, polyethylene glycol, and a cationic lipid. 2. The composition of claim 1 , wherein said at least one nucleic acid agent comprises at least five nucleic acid agents, for down-regulating ATPase subunit A, RNA polymerase III, Inhibitor of apoptosis (IAP), FAS apoptotic inhibitor and α-Tubulin, each of said at least five nucleic acid agent targeting a different gene. 3. The composition of claim 1 , wherein said at least one nucleic acid agent comprises at least six nucleic acid agents, for down-regulating ATPase subunit A, RNA polymerase I, RNA polymerase III, Inhibitor of apoptosis (IAP), FAS apoptotic inhibitor and α-Tubulin, each of said at least six nucleic acid agents for targeting a different gene. 4. The composition of claim 2 , wherein said nucleic acid agents are as set forth in SEQ ID Nos: 1, 13, 27, 30 and 39. 5. The composition of claim 3 , wherein said nucleic acid agents are as set forth in SEQ ID Nos: 1, 4, 7, 10, 13, 16, 19, 22, 25, 27, 30, 33, 36 and 39. 6. The composition of claim 1 , wherein said composition is in solid form. 7. The composition of claim 1 , wherein said composition is in liquid form. 8. The composition of claim 1 , wherein said composition comprises protein. 9. The composition of claim 7 , wherein said liquid is a sucrose solution. 10. The composition of claim 7 , wherein said liquid is a corn syrup solution. 11. The composition of claim 7 , wherein said liquid further comprises a carbohydrate or sugar supplement. 12. The composition of claim 1 , wherein said nucleic acid sequence comprises a sequence complementary to at least 21 nucleotides of Varroa destructor mite messenger RNA (mRNA). 13. The composition of claim 12 , wherein said Varroa destructor mite mRNA encodes a polypeptide selected from the group consisting of ATPase subunit A, RNA polymerase III, IAP, FAS apoptotic inhibitor, and α-Tubulin. 14. The composition of claim 1 , wherein said nucleic acid sequence is greater than 15 base pairs in length. 15. The composition of claim 1 , wherein said nucleic acid sequence is greater than 19 to 25 base pairs in length. 16. The composition of claim 1 , wherein said nucleic acid sequence is greater than 30 base pairs in length. 17. The composition of claim 1 , wherein said at least one nucleic acid agent is selected from the group consisting of a double-stranded RNA (dsRNA), an antisense RNA, and a ribozyme. 18. The composition of claim 17 , wherein said dsRNA is selected from the group consisting of a small inhibitory RNA (siRNA), a short-hairpin RNA (shRNA), and a microRNA (miRNA).

Assignees

Inventors

Classifications

  • against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

  • Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

  • Double-stranded nucleic acids or oligonucleotides · CPC title

  • A23K50/90Primary

    for insects, e.g. bees or silkworms · CPC title

  • Sugars; Polysaccharides · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10801028B2 cover?
An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.
Who is the assignee on this patent?
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd, Beeologics Inc
What technology area does this patent fall under?
Primary CPC classification C12N15/1137. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).